

**Lifetime Probability of Developing and Dying from Cancer, 2016-2018**

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
<b>All Sites*</b>	40.2	2	20.5	5	38.5	3	17.9	6
Brain & ONS	0.7	143	0.5	188	0.5	186	0.4	239
Breast	0.1	727	<0.1	3,260	12.9	8	2.5	39
Colorectal	4.2	24	1.8	57	4.0	25	1.6	62
Esophagus	0.8	126	0.7	137	0.2	433	0.2	513
Hodgkin lymphoma	0.2	434	<0.1	2,792	0.2	517	0	3,683
Kidney & renal pelvis	2.2	46	0.6	175	1.3	79	0.3	311
Larynx	0.5	200	0.2	561	0.1	835	0	2,239
Leukemia	1.9	54	0.9	107	1.3	77	0.7	150
Liver & intrahepatic bile duct	1.5	69	1	97	0.6	157	0.5	182
Lung & bronchus	6.4	16	5	20	6.0	17	4.2	24
Melanoma of skin†	3.7	27	0.4	235	2.5	40	0.2	463
Myeloma	1.0	105	0.5	218	0.7	138	0.4	272
Non-Hodgkin lymphoma	2.4	42	0.8	126	1.9	52	0.6	164
Oral cavity & pharynx	1.7	60	0.4	239	0.7	140	0.2	536
Ovary	--	--	--	--	1.2	85	0.8	119
Pancreas	1.7	59	1.4	71	1.6	61	1.4	73
Prostate	12.5	8	2.4	41	--	--	--	--
Stomach	1.0	98	0.4	239	0.7	152	0.3	351
Testis	0.4	244	<0.1	4,982	--	--	--	--
Thyroid	0.7	149	0.1	1,699	1.8	55	0.1	1,413
Urinary bladder‡	3.8	26	0.9	109	1.2	86	0.3	292
Uterine cervix	--	--	--	--	0.6	159	0.2	461
Uterine corpus	--	--	--	--	3.1	32	0.7	154

\*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic Whites.

‡Includes invasive and in situ cancer cases.

**Source:** Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.9, National Cancer Institute, 2021.